Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival–Cure Model
From MaRDI portal
Publication:3632627
DOI10.1198/016214507000000400zbMath1469.62383OpenAlexW2030118009MaRDI QIDQ3632627
Menggang Yu, Howard M. Sandler
Publication date: 12 June 2009
Published in: Journal of the American Statistical Association (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1198/016214507000000400
Related Items (14)
A characterization of missingness at random in a generalized shared-parameter joint modeling framework for longitudinal and time-to-event data, and sensitivity analysis ⋮ Joint analysis of longitudinal data and competing terminal events in the presence of dependent observation times with application to chronic kidney disease ⋮ Joint modeling of longitudinal proportional measurements and survival time with a cure fraction ⋮ Identifiability of cure models revisited ⋮ Real‐Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models ⋮ A Bayesian Semiparametric Survival Model with Longitudinal Markers ⋮ A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma ⋮ Assessing the association between trends in a biomarker and risk of event with an application in pediatric HIV/AIDS ⋮ Joint models for longitudinal counts and left-truncated time-to event data with applications to health insurance ⋮ Discussion of: ``Predictive comparison of joint longitudinal-survival modeling: a case study illustrating competing approaches ⋮ A joint survival-longitudinal modelling approach for the dynamic prediction of rehospitalization in telemonitored chronic heart failure patients ⋮ Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time-to-Event Data ⋮ Joint modeling of longitudinal and cure-survival data ⋮ A new approach for joint modelling of longitudinal measurements and survival times with a cure fraction
This page was built for publication: Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival–Cure Model